SGI
PBYI icon

Summit Global Investments’s Puma Biotechnology PBYI Stock Holding History

Summit Global Investments’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-46,200
Closed -$324K – 586
2021
Q3 		$324K Buy
46,200
+18,800
+69% +$141K 0.02% 384
2021
Q2 		$252K Buy
+27,400
New +$278K 0.02% 492

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Summit Global Investments's PBYI Position: Q4 2021 in Review

Summit Global Investments sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 46,200 shares — an estimated $324K sold.

Summit Global Investments first reported a position in PBYI in Q2 2021 and held it in 2 quarters. The position peaked at $324K in Q3 2021. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

  • Summit Global Investments reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Summit Global Investments sold 46,200 Puma Biotechnology shares in Q4 2021, an estimated $324K.
  • Summit Global Investments first reported a position in Puma Biotechnology in Q2 2021 and held it in 2 quarters.
  • Summit Global Investments's Puma Biotechnology position peaked at $324K in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on Summit Global Investments's 13F filing for Q4 2021, filed 14 Feb 2022.